NCT00732641 · REGISTRY CONDITION SEARCH

Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE3
Status at capture: COMPLETED
Registry last update: 2017-04-04

This study aims to assess the efficacy of peginterferon α-2b, compared to a control arm not receiving any maintenance treatment, in adult subjects with multiple myeloma who have responded to a prior induction therapy. Peginterferon α-2b will be given once weekly as an injection until disease progression or relapse, or for up to a maximum of 5 years (whichever occurs first).

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Days With Progression Free Survival (PFS)

→

outcome · POSTED

Number of Days of Overall Survival (OS)

→

outcome · POSTED

Number of Participants With Complete Response (CR) to Treatment

→

outcome · POSTED

Number of Participants With Partial Response (PR) to Treatment

→

outcome · POSTED

Number of Participants With Minimal Response (MR) to Treatment

→

outcome · POSTED

Number of Participants With Progressive Disease(PD) or Relapse From CR

→

outcome · POSTED

Quality of Life

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Must demonstrate willingness to participate in the study and to adhere to dose and visit schedules * Must be ≤85 years of age of either sex, and any race * Must have stage II or III multiple myeloma with a histological confirmation consistent with the diagnosis of multiple myeloma (by biopsy of an osteolytic or soft tissue tumour composed of plasma cells or bone marrow aspirate and/or biopsy demonstrating ≥ 10% plasmacytosis). The histological confirmation should have been obtained prior to the induction chemotherapy or bone marrow transplant chemotherapy * May not have received prior interferon for the treatment of multiple myeloma * Must confirm that he/she is practicing adequate contraception * If a female volunteer of childbearing potential, must have a negative serum pregnancy test at Screening/Visit 1 -Must be free of any clinically relevant disease (other than multiple myeloma) that would, in the principal investigator's and/or sponsor's opinion, interfere with the conduct of the study or study evaluations * Must be able to adhere to the dosing and visit schedules * Clinical laboratory tests (complete blood chemistry \[CBC\], blood chemistries, urinalysis) must be consistent with adequate hepatic and renal function, defined as \<2 times upper limit of any laboratory normal (ULN) and adequate hematological functions defined as platelets \> 50,000/mm\^3, Hemoglobin ≥9.0 g/dL, white blood count (WBC) count ≥2000/mm\^3 -Must have a complete, partial or minimal response after either one induction chemotherapy regimen or one myelosuppressive chemotherapeutic treatment followed by peripheral blood stem cell infusion as a first line treatment. Any type of pre-transplant chemotherapy and conditioning regimen is allowed -Performance Status Karnofsky score of ≥60% at time of randomization Exclusion Criteria: * Is a female who is pregnant, or intends to become pregnant during the study * Is nursing, or intends to be nursing during the study * Has used any investigational product within 30 days prior to enrollment * Have any of the following clinical conditions: * Pre existing psychiatric condition, especially depression, or a history of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or suicidal attempt. Subjects with a history of mild depression may be considered for entry into the protocol provided that a pre-treatment assessment of the subject's mental status indicates that the subject is clinically stable and that there is ongoing evaluation of the patient's mental status during the study * Central Nervous System (CNS) trauma or active seizure disorders requiring medication * Significant cardiovascular dysfunction within the previous 6 months before the study starts (eg, angina, congestive heart failure, recent myocardial infarction, severe hypertension or significant arrhythmia) or patient with multigated acquisition (MUGA) or echocardiogram \< 40%; * History of prior malignant disease within the previous 5 years before the study starts, except for surgically cured squamous cell or basal cell skin carcinoma or Stage I cervical carcinoma or cervical carcinoma in situ; * Known severe coagulation disorders, thrombophlebitis or pulmonary embolism or decompensate liver disease; * Uncontrolled diabetes mellitus or thyroid dysfunction (not responsive to therapy); * Severe chronic pulmonary disease (eg, chronic obstructive pulmonary disease); * Has active and/or uncontrolled infection * Is in a situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study * Is participating in any other clinical study * Is on the staff, affiliated with, or a family member of the staff personnel directly involved with this study * Is allergic to or has sensitivity to the study drug or its excipients
healthy Volunteers: false
maximum Age: 85 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
intervention Names
Drug: Peginterferon
label
Peginterferon α-2b
type
EXPERIMENTAL
description
Participants will be observed and will receive no treatment.
label
No Treatment
type
NO_INTERVENTION

interventions

arm Group Labels
Peginterferon α-2b
description
Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
name
Peginterferon
type
DRUG

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 244
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
PFS was defined as response duration while on maintenance therapy. It was the length of time during and after treatment in which a participant was living with the cancer that did not get worse. PFS was calculated from the date of randomization to the date of the first documented tumor progression or relapse.
measure
Number of Days With Progression Free Survival (PFS)
time Frame
Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse)

secondary Outcomes

description
OS was calculated from the date of randomization to the date of death for any cause. Participants alive at the end of study were censored at the last date they were known to be alive. Participants who were still living at the end of the study were censored on the last date they were known to be alive.
measure
Number of Days of Overall Survival (OS)
time Frame
Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse)
description
CR was defined as: * Absence of the original monoclonal paraprotein in serum and urine by immunofixation, maintained for a minimum of 6 weeks; * \<5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy, if biopsy was performed. * No increase in size or number of lytic bone lesions (development of a compression fracture did not include response); * Disappearance of soft tissue plasmocytomas.
measure
Number of Participants With Complete Response (CR) to Treatment
time Frame
Month 9 & Month 18
description
PR was defined as: * At least 50% reduction in the level of the serum monoclonal paraprotein, maintained for a minimum of 6 weeks; * Reduction in 24-hour urinary light chain excretion either by ≥ 90% or to \< 200 mg, maintained for a minimum of 6 weeks; * For patients with non-secretory myeloma only, ≥ 50% reduction in plasma cells in a bone marrow aspirate and on a trephine biopsy, if biopsy was performed, maintained for a minimum of 6 weeks; * At least 50% reduction in the size of soft tissue plasmacytomas; * No increase in size or number of lytic bone lesions.
measure
Number of Participants With Partial Response (PR) to Treatment
time Frame
Month 9 & Month 18
description
MR was defined as: * A 25-49% reduction in the level of the serum monoclonal paraprotein maintained for a minimum of 6 weeks; * Reduction in the 24-hour urinary light chain excretion, which still exceeded 200mg/24 hours, maintained for a minimum of 6 weeks; * For patients with non-secretory myeloma only, 25-49% reduction in plasma cells in a bone marrow aspirate and on a trephine biopsy, if biopsy was performed, maintained for a minimum of 6 weeks; * A 25-49% reduction in the size of soft tissue plasmacytomas; * No increase in the size or number of lityc lesions.
measure
Number of Participants With Minimal Response (MR) to Treatment
time Frame
Month 9 & Month 18
description
PD (for patients not in CR) required one or more of the following: * 25% increase in serum monoclonal paraprotein level, 24-hour urinary light chain excretion, or plasma cells; * Increase in size of existing or development of new bone lesions/soft tissue plasmacytomas; * Development of hypercalcemia. Relapse from CR required at least one of the following: * Reappearance of serum or urinary paraprotein; * \>5% plasma cells; * Development of new lytic bone lesions or soft tissue plasmacytomas or increase in the size of residual bone lesions; * Development of hypercalcemia.
measure
Number of Participants With Progressive Disease(PD) or Relapse From CR
time Frame
Month 9 & Month 18
description
Participants were given the Europen Organization for Research in Cancer Therapy Quality of Life Questionnaire (EORTC QLQ), version 2.0, which consisted of 30 questions. The questionnaire evaluated global health/quality of life and incorporated five functional scales (Physical; Role; Emotional; Cognitive; Social). All of the scales ranged in score from 0 (worst) to 100 (best).
measure
Quality of Life
time Frame
Screening and Last Observation (up to 5 years)

Full study description

brief Summary: This study aims to assess the efficacy of peginterferon α-2b, compared to a control arm not receiving any maintenance treatment, in adult subjects with multiple myeloma who have responded to a prior induction therapy. Peginterferon α-2b will be given once weekly as an injection until disease progression or relapse, or for up to a maximum of 5 years (whichever occurs first).

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-d4834391b6075f7268d5
requested nct id
NCT00732641
primary nct id
NCT00732641
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
cc6ed5523a10671cddacd8d77f1109706c7e373546ba236582a0e9471a5284c1
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-d4834391b6075f7268d5
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00732641
occurrences
context exact
NCT00732641
end
11
exact text
NCT00732641
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/935/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
562295831defc22909b67268d5e067c34280008cb8c775761c16ca35c8f0a288
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice